Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and topical live biotherapeutic products.

Barbara Ryan and John Schroer joined Azitra, Inc.’s board of directors.

"We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets," says Francisco Salva, President and CEO of Azitra, in a news release. "Both Barbara and John are widely recognized leaders in biotech, and their additions to Azitra's board will be invaluable as we grow the company to support clinical trials and our partnership with Bayer."  

Ms. Ryan is a Board Member of Indivior PLC and MiNK Therapeutics, the CEO of Barbara Ryan Advisors, and a Senior Advisor at Ernst & Young. Previously, Ms. Ryan was a Wall Street research analyst, a Managing Director, and Head of Pharmaceutical Research at Deutsche Bank. She began her career covering the pharmaceutical industry at Bear Stearns. She has been the lead analyst on high-profile transactions and has raised over $1.5 billion for emerging biopharma companies in IPOs, follow-ons, PIPEs, and convertible debt transactions. She has led the IR/PR programs, or served as senior strategic investor relations counsel, to firms including Shire, Cardinal Health, Zoetis, Allergan, and Perrigo Agenus, Radius Health, Rafael Holdings, Centrexion, Esperion, ContraFect, Relypsa, Syndax, Barbara is a member of the Editorial Advisory Board of Pharmaceutical Executive magazine where she authors a monthly finance column and is a faculty member at the GLG Institute.

John Schroer is the chief financial officer at Alumis, where he started in March 2022. Previously, he was chief financial officer at ArsenalBio from February 2021 to February 2022. Prior to that role, Mr. Schroer served as chief financial officer and treasurer at Translate Bio. From January 2014 to April 2018, Mr. Schroer served as a director and sector head – healthcare at Allianz Global Investors, a global asset management company. From 2009 to December 2013, he served as president and chief investment officer at Schroer Capital, LP, a financial services company that he founded. Mr. Schroer received a B.S. in history and international relations and an MBA from the University of Wisconsin-Madison.

"Azitra is an innovative company that is bringing much-needed novel therapies to patients suffering from severe skin diseases, which often has few or no therapeutic options," says Ms. Ryan. "I am delighted to join Azitra's board and look forward to working closely with the team on strategies to successfully grow the company and deliver value to both patients and shareholders."